{"id":19689,"date":"2023-04-13T20:17:00","date_gmt":"2023-04-13T12:17:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19689"},"modified":"2024-12-24T20:20:57","modified_gmt":"2024-12-24T12:20:57","slug":"overland-adct-biopharma-achieves-primary-endpoint-in-zynlonta-phase-ii-study-for-r-r-dlbcl","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19689","title":{"rendered":"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL"},"content":{"rendered":"\n

Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China\u2019s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (NYSE: ADCT<\/a>), announced that the primary endpoint has been reached in a Phase II regulatory study. The study assessed the efficacy and safety of Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). The results are in line with those of the global pivotal ADCT-402-201 study and will support a market approval filing for the drug in China.<\/p>\n\n\n\n

Zynlonta’s Ongoing Phase III Study and Potential for NMPA Approval<\/strong>
Zynlonta is also the subject of the confirmatory Phase III ADCT-402-311 study in R\/R DLBCL in China. This study is a global Phase III trial assessing the efficacy and safety of the drug in combination with rituximab compared to rituximab combined with chemotherapy. If Zynlonta obtains conditional approval from the National Medical Products Administration (NMPA), the study will provide scientific evidence for full approval in the R\/R DLBCL indication. The first indication for the drug in China is anticipated to be in the second-line setting for R\/R DLBCL as a combination therapy.<\/p>\n\n\n\n

Global Recognition of Loncastuximab Tesirine<\/strong>
Loncastuximab tesirine was granted fast-track designation in the US in April 2021 for use in adults with r\/r DLBCL who have received at least two lines of systemic therapy. It remains the first and only CD19-targeted ADC globally. A conditional approval was also awarded in the European Union in December 2022, highlighting the drug’s potential impact on the treatment landscape for R\/R DLBCL patients worldwide.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China\u2019s Overland Pharmaceuticals and Swiss…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,2695,16,17,2696,2749,2694,25],"class_list":["post-19689","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-adc-therapeutics","tag-cancer","tag-clinical-trial-results","tag-nyse-adct","tag-overland-adct-biopharma","tag-overland-pharmaceuticals","tag-potential-first-in-class"],"yoast_head":"\nOverland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China\u2019s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (NYSE: ADCT), announced that the primary endpoint has been reached in a Phase II regulatory study. The study assessed the efficacy and safety of Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). The results are in line with those of the global pivotal ADCT-402-201 study and will support a market approval filing for the drug in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19689\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19689\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T12:17:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T12:20:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19689#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19689\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\\\/R DLBCL\",\"datePublished\":\"2023-04-13T12:17:00+00:00\",\"dateModified\":\"2024-12-24T12:20:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19689\"},\"wordCount\":290,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"ADC Therapeutics\",\"Cancer\",\"Clinical trial results\",\"NYSE: ADCT\",\"Overland ADCT BioPharma\",\"Overland Pharmaceuticals\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19689#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19689\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19689\",\"name\":\"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\\\/R DLBCL - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-13T12:17:00+00:00\",\"dateModified\":\"2024-12-24T12:20:57+00:00\",\"description\":\"Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China\u2019s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (NYSE: ADCT), announced that the primary endpoint has been reached in a Phase II regulatory study. The study assessed the efficacy and safety of Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, for the treatment of recurrent\\\/refractory diffuse large B-cell lymphoma (R\\\/R DLBCL). The results are in line with those of the global pivotal ADCT-402-201 study and will support a market approval filing for the drug in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19689#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19689\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19689#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\\\/R DLBCL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL - Insight, China's Pharmaceutical Industry","description":"Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China\u2019s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (NYSE: ADCT), announced that the primary endpoint has been reached in a Phase II regulatory study. The study assessed the efficacy and safety of Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). The results are in line with those of the global pivotal ADCT-402-201 study and will support a market approval filing for the drug in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19689","og_locale":"en_US","og_type":"article","og_title":"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19689","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-13T12:17:00+00:00","article_modified_time":"2024-12-24T12:20:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19689#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19689"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL","datePublished":"2023-04-13T12:17:00+00:00","dateModified":"2024-12-24T12:20:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19689"},"wordCount":290,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","ADC Therapeutics","Cancer","Clinical trial results","NYSE: ADCT","Overland ADCT BioPharma","Overland Pharmaceuticals","Potential first-in-class"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19689#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19689","url":"https:\/\/flcube.com\/?p=19689","name":"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-13T12:17:00+00:00","dateModified":"2024-12-24T12:20:57+00:00","description":"Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China\u2019s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (NYSE: ADCT), announced that the primary endpoint has been reached in a Phase II regulatory study. The study assessed the efficacy and safety of Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). The results are in line with those of the global pivotal ADCT-402-201 study and will support a market approval filing for the drug in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19689#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19689"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19689#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R\/R DLBCL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19689"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19689\/revisions"}],"predecessor-version":[{"id":19690,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19689\/revisions\/19690"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}